Peritoneal dialysis solutions: Nutritional aspects

Peritoneal Dialysis International

Volumn 17, Issue SUPPL. 3, 1997, Pages

  Gokal, Ram ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Malnutrition prevention; Peritoneal dialysis solutions; Solutions, nutritional aspects

Indexed keywords

AMINO ACID; BICARBONATE; BIOMATERIAL; BUFFER; CALCIUM; DIALYSIS FLUID; GLUCAN; GLUCOSE; ICODEXTRIN; LACTIC ACID DERIVATIVE;

ABSORPTION; ARTICLE; HUMAN; NUTRITION; NUTRITIONAL SUPPORT; OSMOLARITY; PERITONEAL DIALYSIS; PH; ULTRAFILTRATION;

ABSORPTION; AMINO ACIDS; BIOCOMPATIBLE MATERIALS; BUFFERS; CALCIUM; DIALYSIS SOLUTIONS; GLUCANS; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTATES; NUTRITION PHYSIOLOGY; NUTRITIONAL SUPPORT; OSMOLAR CONCENTRATION; PERITONEAL DIALYSIS; SODIUM BICARBONATE; ULTRAFILTRATION;

EID: 0030625929     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089701703s20     Document Type: Article

References (27)

1. Gokal R. Peritoneal dialysis. In: Camerson S, Davison AM, Grinfeld JP, et al., eds. Oxford textbook of clinical nephrology. Oxford: Oxford University Press, 1992: 1477-505.
2. Holmes CJ. Biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1993; 13:88-94.
3. Dobbie J. Durability of the peritoneal membrane.Perit Dial Int 1995; 15(Suppl):S87-94.
4. Kopple J, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with amino acid based dialysate. Kidney Int 1995; 47:448-57.
5. Jones MR. Intraperitoneal amino acids: A therapy whose time has come? Perit Dial Int 1995; 15(Suppl): S67-74.
6. Bazzato G, Fracasso A, Gambaro G, Baggio B. Use of glycosaminoglycans to increase efficiency of long term continuous peritoneal dialysis.Lancet 1995;346:740-1.
7. Yasuda T, Ozawa S, Sheba G, et al. D-Lactate metabolism in patients with chronic renal failure undergoing CAPD. Nephron 1993; 63:416-22.
8. Brunkhorst R, Mahiout A. Pyruvate as non-toxic peritoneal dialysate buffer; maintained mesothelial cell integrity and proliferation. J Am Soc Nephrol 1994; 5:410.
9. Liberek T, Topley N, Jörres A, Coles GA, Gahl GM, Williams JD. Peritoneal dialysis fluid inhibition of phagocyte function: Effect of osmolality and glucose concentrations. J Am Soc Nephrol 1993; 3:1508-15.
10. Topley M, Mackenzie R, Peterson M, et al. In vitro testing of potentially biocompatible CAPD fluids. Nephrol Dial Transplant 1991; 6:574-81.
11. Hjelle JT, Miller-Hjelle MA, Dobbie JW. The biology of the mesothelium during peritoneal dialysis. Perit Dial Int 1995; 15(7)(Suppl):S13-28.
12. Mahiout A, Erlerding G, Krautizig S, Brunkhorst R. Production of advanced glycosylation end products (AGE) in the peritoneum of CAPD patients. J Am Soc Nephrol 1994; 5:464.
13. Flessner MF. Osmotic barrier of the parietal peritoneum. Am J Physiol 1994; 267:F861-70.
14. Lamb E, Cattell W, Dawnay A. Glycated albumen in serum and dialysate of patients in CAPD. Clin Sci 1993; 84:619-26.
15. Yamada K, Miyakasa Y, Hamaguchi K.,et al. Immunohistochemical study of human advanced glycosylation end products (AGE) in chronic renal failure. Clin Nephrol 1994; 42:354-61.
16. Millar DJ, Dawnay A. Glycation of albumin with icodextrin. J Am Soc Nephrol 1995; 6:551.
17. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; ii:178-82.
18. Mistry CD, Gokal R, Peers EM, MIDAS Study Group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose in CAPD. Kidney Int 1994; 46:496-503.
19. Stein A, Peers E, Hattersley J, et al. Clinical experience with icodextrin in CAPD patients. Perit Dial Int 1994; 14(Suppl 2):S51-4.
20. Posthuma N, Wee P, Doinker A, Oe RP, Verbrugh HA, Peers E. Improved ultrafiltration in CCPD patients using icodextrin instead of glucose during the long daytime dwell. J Am Soc Nephrol 1995; 6:513.
21. Faller B, Shockley T, Genestier S, et al. A comparative clinical study of peritoneal dialysis solutions containing polyglucose in combination with amino acids. J Am Soc Nephrol 1995; 6:510.
22. Martis L, Serles KD, Nolph K. Calcium carbonate as a phosphate binder. Is there is a need to adjust peritoneal dialysate calcium concentration for patients using CaCo3. Perit Dial Int 1989; 9:325-8.
23. Hutchison A, Freemont AJ, Boulton HF, Gokal R. Low calcium dialysis fluid and oral calcium carbonate in CAPD: A method of controlling hyperphosphataemia whilst minimizing aluminum exposure and hypercalcaemia. Nephrol Dial Transplant 1992; 7:1219-25.
24. Weinreich T, Passlick-Deetjen J, Ritz E, and collaboration of PD Multicenter Study .Am J Kidney Dis 1995; 25:452-60.
25. Cunningham J, Beer J, Coldwell RD, Noon K, Sawyer N, Makin H. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 1992; 7:63-8.
26. Weinreich T, Ritz E, Passlick-Deetjen J. Long-term dialysis with low calcium solution in CAPD -Effects of bone mineral metabolism. Perit Dial Int 1996; 16:260-8.
27. Hutchison A, Turner K, Gokal R. Effect of long term therapy with 1.25 mmol/L calcium PD fluid on incidence of peritonitis in CAPD. Perit Dial Int 1992; 12:321-5.